Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
Summary
Candel Therapeutics agreed to sell about 3.2 million shares in a registered direct offering priced at $4.67 per share. The company expects to raise roughly $15 million before expenses and close the deal on June 25, 2025. It plans to use the proceeds for launch readiness, medical affairs, pre-commercialization work, and general corporate purposes. Candel also said the funds will support preparation for a Biologics License Application for CAN-2409 in prostate cancer expected in the fourth quarter of 2026.
Funding
Amount
$15.0M
Total raised
Date
June 24, 2025
Announcement date
Investors
-
Lead investors
Company
https://www.candeltx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected